Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Neurooncol ; 133(1): 97-105, 2017 05.
Article in English | MEDLINE | ID: mdl-28555423

ABSTRACT

Proton magnetic resonance spectroscopy (1H-MRS) has shown promise in distinguishing recurrent high-grade glioma from posttreatment radiation effect (PTRE). The purpose of this study was to establish objective 1H-MRS criteria based on metabolite peak height ratios to distinguish recurrent tumor (RT) from PTRE. A retrospective analysis of magnetic resonance imaging and 1H-MRS data was performed. Spectral metabolites analyzed included N-acetylaspartate, choline (Cho), creatine (Cr), lactate (Lac), and lipids (Lip). Quantitative 1H-MRS criteria to differentiate RT from PTRE were identified using 81 biopsy-matched spectral voxels. A receiver operating characteristic curve analysis was conducted for all metabolite ratio combinations with the pathology diagnosis as the classification variable. Forward discriminant analysis was used to identify ratio variables that maximized the correct classification of RT versus PTRE. Our results were applied to 205 records without biopsy-matched voxels to examine the percent agreement between our criteria and the radiologic diagnoses. Five ratios achieved an acceptable balance [area under the curve (AUC) ≥ 0.700] between sensitivity and specificity for distinguishing RT from PTRE, and each ratio defined a criterion for diagnosing RT. The ratios are as follows: Cho/Cr > 1.54 (sensitivity 66%, specificity 79%), Cr/Cho ≤ 0.63 (sensitivity 65%, specificity 79%), Lac/Cho ≤ 2.67 (sensitivity 85%, specificity 58%), Lac/Lip ≤ 1.64 (sensitivity 54%, specificity 95%), and Lip/Lac > 0.58 (sensitivity 56%, specificity 95%). Application of our ratio criteria in prospective studies may offer an alternative to biopsy or visual spectral pattern recognition to distinguish RT from PTRE in patients with gliomas.


Subject(s)
Brain Neoplasms/diagnostic imaging , Brain/diagnostic imaging , Glioma/diagnostic imaging , Neoplasm Recurrence, Local/diagnostic imaging , Proton Magnetic Resonance Spectroscopy , Radiation Injuries/diagnostic imaging , Adult , Area Under Curve , Brain/metabolism , Brain/radiation effects , Brain Neoplasms/metabolism , Brain Neoplasms/radiotherapy , Diagnosis, Differential , Discriminant Analysis , Female , Glioma/metabolism , Glioma/radiotherapy , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Necrosis/diagnostic imaging , Necrosis/etiology , Necrosis/metabolism , Neoplasm Recurrence, Local/metabolism , ROC Curve , Radiation Injuries/etiology , Radiation Injuries/metabolism , Retrospective Studies
2.
J Virol ; 85(23): 12830-4, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21937660

ABSTRACT

We analyzed xenotropic murine leukemia virus-related virus (XMRV) integration site sequences previously identified from human prostate tissues for single-nucleotide polymorphisms (SNPs) to discriminate between patient and potential cell line sources of the proviruses. The SNPs of two integration sites were identical to those in cell lines but not the patients, whereas the data on the remaining 12 integration sites were inconclusive. Our results provide direct evidence for contamination during analysis of XMRV integration sites.


Subject(s)
Polymorphism, Single Nucleotide/genetics , Prostatic Neoplasms/genetics , Prostatic Neoplasms/virology , Retroviridae Infections/virology , Virus Integration/genetics , Xenotropic murine leukemia virus-related virus/genetics , Animals , Base Sequence , Humans , Male , Mice , Molecular Sequence Data , Proviruses/genetics , Retroviridae Infections/genetics , Sequence Homology, Nucleic Acid , Tumor Cells, Cultured , Xenotropic murine leukemia virus-related virus/isolation & purification , Xenotropic murine leukemia virus-related virus/pathogenicity
SELECTION OF CITATIONS
SEARCH DETAIL